Citigroup Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its price target boosted by Citigroup from $120.00 to $125.00 in a report issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Citigroup’s price target indicates a potential upside of 9.49% from the company’s previous close.

Several other equities analysts have also recently issued reports on MRK. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research report on Friday, February 13th. Cantor Fitzgerald lifted their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a report on Thursday, January 8th. Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Wells Fargo & Company increased their price target on Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

Merck & Co., Inc. Trading Down 0.0%

Shares of Merck & Co., Inc. stock opened at $114.17 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The company has a market capitalization of $282.27 billion, a P/E ratio of 15.68, a PEG ratio of 2.21 and a beta of 0.27. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $125.14. The company’s fifty day moving average is $115.81 and its two-hundred day moving average is $100.75.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same period in the prior year, the company earned $1.72 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP David Michael Williams sold 5,000 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president directly owned 30,838 shares of the company’s stock, valued at approximately $3,759,460.58. This represents a 13.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 320,176 shares of company stock worth $38,281,735 in the last three months. Company insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $25,000. Darwin Wealth Management LLC grew its position in Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after buying an additional 216 shares during the period. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $26,000. Finally, Kilter Group LLC purchased a new position in Merck & Co., Inc. in the second quarter valued at about $27,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.